share_log

BTIG Maintains Buy on MaxCyte, Lowers Price Target to $8

Moomoo 24/7 ·  Mar 13 08:03

BTIG analyst Mark Massaro maintains MaxCyte (NASDAQ:MXCT) with a Buy and lowers the price target from $10 to $8.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment